Immune mechanisms of ischemia-reperfusion injury in transplantation


All allografts suffer a number of unavoidable ischemic insults. These, starting with brain death and ending with reperfusion, are very troublesome, as ischemia-reperfusion injury (IRI) is demonstrated to be a major cause of allograft damage in various types of transplantations. To counter the threat this poses to allograft function, investigators have worked diligently over the past decades in clinical settings and in the laboratory to understand the pathophysiology and immune mechanism underlying IRI hoping to ultimately devise strategies that lessen its detrimental effects on allografts. Herein, we review the major immune components of the IRI dynamic process. Better understanding of the cellular pathophysiological processes underlying IRI will hopefully result in the design of more targeted therapies to prevent the injury, hasten repair, and minimize chronic progressive allograft damage.

Share and Cite:

Khalifian, S. , Broyles, J. , Tuffaha, S. , Alrakan, M. , Ibrahim, Z. and Sarhane, K. (2013) Immune mechanisms of ischemia-reperfusion injury in transplantation. Open Journal of Immunology, 3, 158-164. doi: 10.4236/oji.2013.33020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Palmer, S.M., Burch, L.H., Davis, R.D., Herczyk, W.F., Howell, D.N., Reinsmoen, N.L. and Schwartz, D.A. (2003) The role of innate immunity in acute allograft rejection after lung transplantation. American Journal of Respiratory and Critical Care Medicine, 168, 628-632. doi:10.1164/rccm.200303-447OC
[2] Krüger, B., Krick, S., Dhillon, N., Lerner, S.M., Ames, S., Bromberg, J.S., Lin, M., Walsh, L., Vella, J., Fischereder, M., Kr?mer, B.K., Colvin, R.B., Heeger, P.S., Murphy, B.T. and Schr?ppel, B. (2009) Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proceedings of the National Academy of Sciences of the United States of America, 106, 3390-3395. doi:10.1073/pnas.0810169106
[3] Zhai, Y., Shen, X., O’Connell, R., Gao, F., Lassman, C., Busuttil, R.W., Cheng, G. and Kupiec-Weglinski, J.W. (2004) Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. Journal of Immunology, 173, 7115-7119.
[4] Halloran, P.F., Homik, J., Goes, N., Lui, S.L., Urmson, J., Ramassar, V. and Cockfield, S.M. (1997) The “injury response”: A concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplantation Proceedings, 29, 79-81. doi:10.1016/S0041-1345(96)00015-2
[5] Kreisel, D. and Goldstein, D.R. (2013) Innate immunity and organ transplantation: Focus on lung transplantation. Transplant International: Official Journal of the European Society for Organ Transplantation, 26, 2-10. doi:10.1111/j.1432-2277.2012.01549.x
[6] Villamaria, C.Y., Rasmussen, T.E., Spencer, J.R., Patel, S. and Davis, M.R. (2012) Microvascular porcine model for the optimization of vascularized composite tissue transplantation. The Journal of Surgical Research, 178, 452- 459. doi:10.1016/j.jss.2012.03.051
[7] Shimizu, F., Okamoto, O., Katagiri, K., Fujiwara, S. and Wei, F.-C. (2010) Prolonged ischemia increases severity of rejection in skin flap allotransplantation in rats. Micryosurgery, 30, 132-137.
[8] Kuo, Y.-R., Wang, F.-S., Jeng, S.-F., Huang, H.-C., Wei, F.-C. and Yang, K.D. (2004) Nitrosoglutathione modulation of platelet activation and nitric oxide synthase expression in promotion of flap survival after ischemia/reperfusion injury. The Journal of Surgical Research, 119, 92-99. doi:10.1016/j.jss.2003.08.006
[9] Siemionow, M. and Arslan, E. (2004) Ischemia/reperfusion injury: A review in relation to free tissue transfers. Microsurgery, 24, 468-475. doi:10.1002/micr.20060
[10] Wang, W.Z., Baynosa, R.C. and Zamboni, W.A. (2011) Update on ischemia-reperfusion injury for the plastic surgeon: 2011. Plastic and Reconstructive Surgery, 128, 685e-692e. doi:10.1097/PRS.0b013e318230c57b
[11] Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell, 124, 783-801. doi:10.1016/j.cell.2006.02.015
[12] Methe, H., Zimmer, E., Grimm, C., Nabauer, M. and Koglin, J. (2004) Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation, 78, 1324-1331. doi:10.1097/01.TP.0000137930.40597.03
[13] Akira, S., Takeda, K. and Kaisho, T. (2001) Toll-like receptors: Critical proteins linking innate and acquired immunity. Nature Immunology, 2, 675-680. doi:10.1038/90609
[14] Matzinger, P. (1998) An innate sense of danger. Seminars in Immunology, 10, 399-415. doi:10.1006/smim.1998.0143
[15] Ionita, M.G., Arslan, F., de Kleijn, D.P.V. and Pasterkamp, G. (2010) Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. Journal of Innate Immunity, 2, 307-315. doi:10.1159/000314270
[16] Gill, R.G. (2010) NK cells: Elusive participants in transplantation immunity and tolerance. Current Opinion in Immunology, 22, 649-654. doi:10.1016/j.coi.2010.09.005
[17] Zhang, M. and Carroll, M.C. (2007) Natural antibody mediated innate autoimmune response. Molecular Immunology, 44, 103-110. doi:10.1016/j.molimm.2006.06.022
[18] Wanderer, A.A. (2008) Ischemic-reperfusion syndromes: Biochemical and immunologic rationale for IL-1 targeted therapy. Clinical Immunology, 128, 127-132. doi:10.1016/j.clim.2008.03.514
[19] Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R. and Tsung, A. (2008) HMGB1: Endogenous danger signaling. Molecular Medicine, 14, 476-484. doi:10.2119/2008-00034.Klune
[20] Tsung, A., Klune, J.R., Zhang, X., Jeyabalan, G., Cao, Z., Peng, X., Stolz, D.B., Geller, D.A., Rosengart, M.R. and Billiar, T.R. (2007) HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. The Journal of Experimental Medicine, 204, 2913- 2923. doi:10.1084/jem.20070247
[21] Wu, H., Chen, G., Wyburn, K.R., Yin, J., Bertolino, P., Eris, J.M., Alexander, S.I., Sharland, A.F. and Chadban, S.J. (2007) TLR4 activation mediates kidney ischemia/ reperfusion injury. The Journal of Clinical Investigation, 117, 2847-2859. doi:10.1172/JCI31008
[22] Reichenbach, D.K., Li, Q., Hoffman, R.A., Williams, A.L., Shlomchik, W.D., Rothstein, D.M., Demetris, A.J. and Lakkis, F.G. (2013) Allograft outcomes in outbred mice. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 13, 580-588. doi:10.1111/ajt.12056
[23] Khalil, A.A., Aziz, F.A. and Hall, J.C. (2006) Reperfusion injury. Plastic and Reconstructive Surgery, 117, 1024- 1033. doi:10.1097/01.prs.0000204766.17127.54
[24] Tullius, S.G., Reutzel-Selke, A., Egermann, F., Nieminen- Kelh?, M., Jonas, S., Bechstein, W.O., Volk, H.D. and Neuhaus, P. (2000) Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction. Journal of the American Society of Nephrology, 11, 1317- 1324.
[25] Morelli, A.E. and Thomson, A.W. (2007) Tolerogenic dendritic cells and the quest for transplant tolerance. Nature Reviews Immunology, 7, 610-621. doi:10.1038/nri2132
[26] Kaufman, C.L., Ouseph, R., Blair, B., Kutz, J.E., Tsai, T.M., Scheker, L.R., Tien, H.Y., Moreno, R., Ozyurekoglu, T., Banegas, R., Murphy, E., Burns, C.B., Zaring, R., Cook, D.F. and Marvin, M.R. (2012) Graft vasculopathy in clinical hand transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 12, 1004-1016. doi:10.1111/j.1600-6143.2011.03915.x
[27] Hautz, T., Wolfram, D., Grahammer, J., Starzl, R., Krapf, C., Pratschke, J., Lee, W.P.A., Brandacher, G. and Schneeberger, S. (2012) Mechanisms and mediators of inflamemation: Potential models for skin rejection and targeted therapy in vascularized composite allotransplantation. Clinical & Developmental Immunology, 2012, 757 310.
[28] Caterson, E.J., Lopez, J., Medina, M., Pomahac, B. and Tullius, S.G. (2013) Ischemia-reperfusion injury in vascularized composite allotransplantation. The Journal of Craniofacial Surgery, 24, 51-56. doi:10.1097/SCS.0b013e31827104e1
[29] Pradka, S.P., Ong, Y.S., Zhang, Y., Davis, S.J., Baccarani, A., Messmer, C., Fields, T.A., Erdmann, D., Klitzman, B. and Levin, L.S. (2009) Increased signs of acute rejection with ischemic time in a rat musculocutaneous allotransplant model. Transplantation Proceedings, 41, 531-536. doi:10.1016/j.transproceed.2009.01.021
[30] Unadkat, J.V., Schneeberger, S., Horibe, E.H., Goldbach, C., Solari, M.G., Washington, K.M., Gorantla, V.S., Cooper, G.M., Thomson, A.W. and Lee, W.P.A. (2010) Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 10, 251- 261. doi:10.1111/j.1600-6143.2009.02941.x
[31] Khalifian, S., Cooney, D.S., Lee, W.P.A. and Brandacher, G. (2013) The role of ischemia-reperfusion injury in reconstructive transplantation. Journal of Transplantation Technologies & Research, S3.
[32] Sarhane, K.A., Ibrahim, Z., Leto Barone, A.A., Cooney, D.S., Lee, W.P.A. and Brandacher, G. (2012) Minimization of Immunosuppression and Tolerance Induction in Reconstructive Transplantation. Current Surgery Reports, 1, 40-46. doi:10.1007/s40137-012-0008-4
[33] Opelz, G. and Wujciak, T. (1994) The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. The New England Journal of Medicine, 330, 816-819. doi:10.1056/NEJM199403243301203
[34] Tesar, B.M., Zhang, J., Li, Q. and Goldstein, D.R. (2004) TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor signal adaptor protein. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 4, 1429-1439. doi:10.1111/j.1600-6143.2004.00544.x
[35] McKay, D., Shigeoka, A., Rubinstein, M., Surh, C. and Sprent, J. (2006) Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. European Journal of Immunology, 36, 1994-2002. doi:10.1002/eji.200636249
[36] Hutton, M.J.H., Westwell-Roper, C., Soukhatcheva, G., Plesner, A., Dutz, J.P. and Verchere, C.B. (2009) Islet allograft rejection is independent of toll-like receptor signaling in mice. Transplantation, 88, 1075-1080. doi:10.1097/TP.0b013e3181bd3fe2
[37] Ducloux, D., Deschamps, M., Yannaraki, M., Ferrand, C., Bamoulid, J., Saas, P., Kazory, A., Chalopin, J.-M. and Tiberghien, P. (2005) Relevance of toll-like receptor-4 polymorphisms in renal transplantation. Kidney International, 67, 2454-2461. doi:10.1111/j.1523-1755.2005.00354.x
[38] Walker, W.E., Nasr, I.W., Camirand, G., Tesar, B.M., Booth, C.J. and Goldstein, D.R. (2006) Absence of innate MyD88 signaling promotes inducible allograft acceptance. Journal of Immunology, 177, 5307-5316.
[39] Braudeau, C., Ashton-Chess, J., Giral, M., Dugast, E., Louis, S., Pallier, A., Braud, C., Moreau, A., Renaudin, K., Soulillou, J.-P. and Brouard, S. (2008) Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation, 86, 130-136. doi:10.1097/TP.0b013e31817b8dc5
[40] Thornley, T.B., Brehm, M.A., Markees, T.G., Shultz, L.D., Mordes, J.P., Welsh, R.M., Rossini, A.A. and Greiner, D.L. (2006) TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. Journal of Immunology, 176, 1561-1570.
[41] Chen, L., Wang, T., Zhou, P., Ma, L., Yin, D., Shen, J., Molinero, L., Nozaki, T., Phillips, T., Uematsu, S., Akira, S., Wang, C.-R., Fairchild, R.L., Alegre, M.-L. and Chong, A. (2006) TLR engagement prevents transplantation tolerance. American Journal of Transplantation, 6, 2282- 2291. doi:10.1111/j.1600-6143.2006.01489.x
[42] Sarhane, K. (2012) Tissue CLN3?: A potential biomarker for breast cancer? M.S. Thesis, American University of Beirut, Beirut.
[43] Landin, L., Cavadas, P.C., Garcia-Cosmes, P., Thione, A., Vera-Sempere, F. (2011) Perioperative ischemic injury and fibrotic degeneration of muscle in a forearm allograft: Functional follow-up at 32 months post transplantation. Annals of Plastic Surgery, 66, 202-209. doi:10.1097/SAP.0b013e318206a365
[44] Chalasani, G., Li, Q., Konieczny, B.T., Smith-Diggs, L., Wrobel, B., Dai, Z., Perkins, D.L., Baddoura, F.K. and Lakkis, F.G. (2004) The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. Journal of Immunology, 172, 7813-7820.
[45] Boucek, M.M., Aurora, P., Edwards, L.B., Taylor, D.O., Trulock, E.P., Christie, J., Dobbels, F., Rahmel, A.O., Keck, B.M. and Hertz, M.I. (2007) Registry of the International society for heart and lung transplantation: Tenth official pediatric heart transplantation report—2007. The Journal of Heart and Lung Transplantation, 26, 796-807. doi:10.1016/j.healun.2007.06.006
[46] Salahudeen, A.K., Haider, N. and May, W. (2004) Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney International, 65, 713-718. doi:10.1111/j.1523-1755.2004.00416.x
[47] Ojo, A.O., Wolfe, R.A., Held, P.J., Port, F.K. and Schmouder, R.L. (1997) Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation, 63, 968-974. doi:10.1097/00007890-199704150-00011
[48] Lee, W.P., Yaremchuk, M.J., Pan, Y.C., Randolph, M.A., Tan, C.M. and Weiland, A.J. (1991) Relative antigenicity of components of a vascularized limb allograft. Plastic and Reconstructive Surgery, 87, 401-411. doi:10.1097/00006534-199103000-00001
[49] Ben Mosbah, I., Mouchel, Y., Pajaud, J., Ribault, C., Lucas, C., Laurent, A., Boudjema, K., Morel, F., Corlu, A. and Compagnon, P. (2012) Pretreatment with mangafodipir improves liver graft tolerance to ischemia/reperfusion injury in rat. PloS One, 7, e50235. doi:10.1371/journal.pone.0050235
[50] Coriat, R., Leconte, M., Kavian, N., Bedda, S., Nicco, C., Chereau, C., Goulvestre, C., Weill, B., Laurent, A. and Batteux, F. (2011) Mangafodipir protects against hepatic ischemia-reperfusion injury in mice. PloS One, 6, e27005. doi:10.1371/journal.pone.0027005
[51] Kaizu, T., Ikeda, A., Nakao, A., Tsung, A., Toyokawa, H., Ueki, S., Geller, D.A. and Murase, N. (2008) Protection of transplant-induced hepatic ischemia/reperfusion injury with carbon monoxide via MEK/ERK1/2 pathway down- regulation. American Journal of Physiology. Gastrointestinal and Liver Physiology, 294, G236-G244. doi:10.1152/ajpgi.00144.2007
[52] Lai, I.-R., Chang, K.-J., Tsai, H.-W. and Chen, C.-F. (2008) Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction. Transplantation, 85, 732-738. doi:10.1097/TP.0b013e3181664e70
[53] Sadis, C., Teske, G., Stokman, G., Kubjak, C., Claessen, N., Moore, F., Loi, P., Diallo, B., Barvais, L., Goldman, M., Florquin, S. and Le Moine, A. (2007) Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PloS One, 2, e469. doi:10.1371/journal.pone.0000469
[54] Fan, J., Jing, F., Dang, S. and Zhang, W. (2013) Protective effects of bifunctional platelet GPIIIa49-66 ligand on myocardial ischemia-reperfusion injury in rats. Open Journal of Immunology, 5, 15-20.
[55] Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Elbelghiti, R., Cung, T.T., Bonnefoy, E., Angoulvant, D., Macia, C., Raczka, F., Sportouch, C., Gahide, G., Finet, G., André-Fou?t, X., Revel, D., Kirkorian, G., Monassier, J.-P., Derumeaux, G. and Ovize, M. (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. The New England Journal of Medicine, 359, 473-481. doi:10.1056/NEJMoa071142

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.